E2F1 and neoplasm: Treatment with abemaciclib of rats bearing esophageal adenocarcinoma xenografts, established from three different cell lines, resulted in tumor volume reduction and down-regulation of cyclin D, CDK4, CDK6 and E2F1, compared with rats treated with placebo [22].